Valve-Sparing Root Replacement Following Congenital Heart Disease Repair: Lesion-Specific Technical Considerations.

World J Pediatr Congenit Heart SurgMay 19, 2026 (epub)
Case ReportCardiothoracic Surgery

Yuchen Cao, Masaaki Koide, Yoshifumi Kunii et al.

✦ AI-curated · Sources linked

Case in brief

This report details three adult cases of valve-sparing root replacement (VSRR) performed after congenital heart disease repairs, specifically for perimembranous ventricular septal defect, annulus-sparing tetralogy of Fallot, and the Ross procedure. In two cases involving prior VSD closure, the right coronary cusp sinus was easily dissected, avoiding complications. The Ross procedure was executed without technical issues, highlighting the importance of understanding individual anatomical variations.

Diagnostic / clinical pearl

Clinicians should recognize that careful consideration of lesion-specific anatomy is crucial for the successful implementation of valve-sparing root replacement in patients with a history of congenital heart disease repair.

Source

PubMed · PMID 42153970

Published in World J Pediatr Congenit Heart Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiothoracic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.